Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60910 | 1.00 | BLM (0.31) | BLMSMN1; SMN2HIF1A | |
| D-Histidine SCHEMBL15663595 | 0.87 | SLC7A5 (0.38) | BLMHIF1A | |
| SCHEMBL1331226 | 0.84 | BLM (0.32) | BLMSMN1; SMN2HIF1A | |
| SCHEMBL3510446 | 0.84 | BLM (0.32) | BLMSMN1; SMN2HIF1A | |
| SCHEMBL3291889 | 0.83 | HRH4 (0.32) | BLMSMN1; SMN2HIF1A | |
| SCHEMBL59405 | 0.81 | BLM (0.47) | BLMSMN1; SMN2HIF1A | |
| SCHEMBL163221 | 0.81 | BLM (0.47) | BLMSMN1; SMN2HIF1A | |
| SCHEMBL26913087 | 0.81 | BLM (0.30) | BLMSMN1; SMN2HIF1A | |
| SCHEMBL10713853 | 0.81 | BLM (0.30) | BLMSMN1; SMN2HIF1A | |
| SCHEMBL59406 | 0.81 | BLM (0.47) | BLMSMN1; SMN2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3250191-B1 | TABLETS COMPRISING GLP-1 AGONIST AND ENTERIC COATING | NOVO NORDISK AS (DK) | 2024-01-17 | — | — | EP | claimed |
| EP-2637698-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2022-04-20 | — | — | EP | claimed |
| CN-107205948-B | Tablets comprising a GLP-1 agonist and an enteric coating | 诺和诺德股份有限公司 | 2021-12-14 | — | — | CN | claimed |
| US-11117947-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2021-09-14 | — | — | US | claimed |
| US-11034746-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2021-06-15 | — | — | US | claimed |
| US-10604554-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2020-03-31 | — | — | US | claimed |
| US-20200079834-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2020-03-12 | — | — | US | claimed |
| US-10308700-B2 | GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2019-06-04 | — | — | US | claimed |
| US-10265384-B2 | Tablets comprising GLP-1 agonist and enteric coating | NOVO NORDISK A/S (DK) | 2019-04-23 | — | — | US | claimed |
| EP-3225631-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2019-01-09 | — | — | EP | claimed |
| US-7893017-B2 | Acylation; point mutations; site-directed mutagenesis; hyperglycemia; diabetes | NOVO NORDISK A/S (DK) | 2011-02-22 | — | — | US | claimed |
| EP-1863839-B1 | ACYLATED GLP-1 COMPOUNDS | NOVO NORDISK AS (DK) | 2010-08-04 | — | — | EP | claimed |
| US-20090156478-A1 | Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2009-06-18 | — | — | US | claimed |
| US-20080207507-A1 | Extended Glp-1 Compounds | NOVO NORDISK A/S (DK) | 2008-08-28 | — | — | US | claimed |
| CN-101133082-A | Acylated GLP-1 compounds | NOVO NORDISK AS (DK) | 2008-02-27 | — | — | CN | claimed |
| CN-101128214-A | Extended GLP-1 compounds | NOVO NORDISK AS (DK) | 2008-02-20 | — | — | CN | claimed |
| EP-1863521-A1 | EXTENDED GLP-1 COMPOUNDS | Novo Nordisk A/S (DK) | 2007-12-12 | — | — | EP | claimed |
| EP-1863839-A2 | ACYLATED GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2007-12-12 | — | — | EP | claimed |
| WO-2006097538-A1 | EXTENDED GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2006-09-21 | — | — | WO | claimed |
| WO-2006097537-A2 | ACYLATED GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2006-09-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207507-A1 | Extended Glp-1 Compounds | GLP1R, GIPR, IAPP | BLM 2791/4885SMN1; SMN2 1213/4885HIF1A 2586/4885 |
| US-20090156478-A1 | Acylated GLP-1 Compounds | GLP1R, GIPR, GCGR | BLM 4498/4885SMN1; SMN2 2903/4885HIF1A 3023/4885 |
| US-10604554-B2 | Double-acylated GLP-1 derivatives | GLP1R, GIPR, GPR119 | BLM 4665/4885SMN1; SMN2 3591/4885HIF1A 973/4885 |
| US-10308700-B2 | GLP-1 derivatives | GLP1R, GIPR, GCG | BLM 4041/4885SMN1; SMN2 4310/4885HIF1A 524/4885 |
| US-11117947-B2 | Double-acylated GLP-1 derivatives | GLP1R, SLC5A1, IAPP | BLM 4807/4885SMN1; SMN2 4151/4885HIF1A 1028/4885 |
| US-10265384-B2 | Tablets comprising GLP-1 agonist and enteric coating | GLP1R, GIPR, SLC10A2 | BLM 4733/4885SMN1; SMN2 1133/4885HIF1A 4386/4885 |
| US-11034746-B2 | Double-acylated GLP-1 derivatives | GLP1R, SLC5A1, IAPP | BLM 4814/4885SMN1; SMN2 4071/4885HIF1A 1038/4885 |
| US-20200079834-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | GLP1R, SLC5A1, IAPP | BLM 4807/4885SMN1; SMN2 4151/4885HIF1A 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.